Related Experiment Video

Updated: Sep 5, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways

Fei Wang1, Chong Yuan1, Bo Liu2,3

  • 1Faculty of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, China.

Journal of Translational Medicine
|July 6, 2022
PubMed
Abstract

Insights

Syringin, a compound from Acanthopanax senticosus, inhibits breast cancer (BC) progression by targeting key genes like PIK3CA and HRAS. This study elucidates its anti-BC mechanisms and potential as an adjuvant therapy.

Area of Science:

  • Pharmacology
  • Bioinformatics
  • Oncology

Background:

  • Breast cancer (BC) is a leading cause of cancer mortality worldwide.
  • Syringin exhibits anti-tumor properties, but its specific anti-BC effects and mechanisms require elucidation.

Purpose of the Study:

  • To investigate the anti-breast cancer efficacy of Syringin.
  • To identify the molecular targets and pathways involved in Syringin's anti-BC action.
  • To explore Syringin's potential as an adjuvant therapy for breast cancer.

Main Methods:

  • Syringin isolation from Acanthopanax senticosus (ASH) using solvent extraction and chromatography.
  • Bioinformatic analysis to identify hub targets of Syringin against BC.
  • In vitro experiments to validate Syringin's effects on BC cell proliferation, migration, and apoptosis.

Main Results:

  • Syringin was isolated and characterized using LC-MS, NMR, and HPLC.
  • Bioinformatics identified MAP2K1, PIK3CA, HRAS, EGFR, Caspase3, and PTGS2 as hub targets.
  • PIK3CA and HRAS were linked to BC patient survival; specific ceRNA pathways were identified.
  • In vitro studies confirmed Syringin's inhibition of BC cell proliferation and migration, and promotion of apoptosis.

Conclusions:

  • Syringin exerts anti-breast cancer effects through the PI3K-AKT-PTGS2 and EGFR-RAS-RAF-MEK-ERK pathways.
  • PIK3CA and HRAS are identified as crucial hub genes for Syringin's anti-BC activity and potential adjuvant treatment.
Keywords:
Acanthopanax senticosus (Rupr. & Maxim.) HarmsBioinformaticsBreast cancerHub genesMechanism of actionSyringin

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K